Cut through the clinical noise. Find treatments that work.
We analyze clinical trial data, verify provider credentials, and map the real costs of emerging neurotechnology treatments—so you don't have to rely on marketing brochures.
The neurotech industry is growing faster than clinical oversight.
Between 2018 and 2023, the number of clinics offering emerging neurological treatments grew by over 400%.
While the underlying science (like TMS for treatment-resistant depression) is robust, the patient experience is a minefield of opaque pricing, varying provider expertise, and overpromising marketing.
We built Neurotech Centre to provide the unbiased, structured data patients need to evaluate these interventions objectively.
What we track:
-
Clinical Efficacy Rates Aggregated from peer-reviewed phase II/III trials, separating remission rates from simple response rates.
-
True Cost & Insurance Out-of-pocket averages, CPT codes for superbills, and actual reimbursement probabilities.
-
Provider Credentials Differentiating between board-certified psychiatrists, CRNAs, and non-medical practitioners operating clinics.
Intervention Profiles
Detailed analysis of the most prominent neurotechnology and psychedelic-assisted therapies currently available outside of clinical trials.
Transcranial Magnetic Stimulation (TMS)
Non-invasive magnetic pulses applied to specific areas of the brain to stimulate nerve cells, primarily used for treatment-resistant depression.
Ketamine Therapy
An NMDA receptor antagonist administered via IV, IM, or nasal spray, known for rapid-acting antidepressant effects and promoting neuroplasticity.
Neurofeedback (EEG Biofeedback)
Real-time monitoring of brainwave activity (EEG) used to train the brain to self-regulate, commonly marketed for ADHD and anxiety.
How to evaluate a clinic.
Not all clinics operate to the same standard. We evaluate providers across four primary axes. Use this matrix when conducting initial consultations.
| Criteria | Red Flags | Acceptable | Gold Standard |
|---|---|---|---|
| Medical Oversight | Medical director is off-site, never evaluates patients personally. Operated solely by technicians. | Initial evaluation by NP or PA. Medical director reviews charts but isn't present for treatments. | Board-certified psychiatrist conducts initial evaluation and is on-site during treatments (especially for Ketamine). |
| Intake & Assessment | Brief online questionnaire. Guaranteed approval. Focus is entirely on securing a deposit. | Standard clinical interview. Review of past medical records if provided by patient. | Comprehensive psychiatric evaluation. Coordination with patient's existing care team before approval. |
| Outcome Tracking | No standardized tracking. Relies entirely on patient anecdotal feedback. | Administers PHQ-9 or GAD-7 at beginning and end of treatment course. | Utilizes standardized scales weekly. Adjusts treatment protocols based on data. Publishes clinic-wide aggregate outcomes. |
| Financial Transparency | Refuses to provide exact pricing upfront. High-pressure sales tactics for "packages." | Clear out-of-pocket pricing. Provides superbills for patient to submit to insurance. | In-network with major payers (for TMS). Pre-authorizes treatments. Transparent fee schedule on website. |
Treatment Pathways by Condition
Treatment-Resistant Depression (TRD)
Defined as inadequate response to at least two different antidepressant trials.
TMS (Transcranial Magnetic Stimulation)
Ketamine (IV/IM) or Spravato (Esketamine)
PTSD & Trauma
Post-Traumatic Stress Disorder refractory to standard psychotherapy and SSRIs.
Ketamine-Assisted Psychotherapy (KAP)
MDMA-Assisted Therapy (Pending FDA status)
Patient Tools
We build interactive calculators and assessment tools to help you navigate the financial and clinical realities of treatment.
View all 12 toolsFrequently Asked Questions
It depends entirely on the specific treatment and your diagnosis:
- TMS: Widely covered for Major Depressive Disorder (MDD) if you have failed 2-4 standard antidepressants (depending on the insurer). Coverage for OCD is increasing but less universal.
- Spravato (Esketamine): Covered by many insurers for Treatment-Resistant Depression, but requires prior authorization.
- IV Ketamine: Rarely covered by insurance as it is considered an off-label use, though some clinics will provide a superbill for the psychiatric evaluation portion.
- Neurofeedback: Very rarely covered by commercial insurance for mental health conditions.
No. We maintain strict independence. We do not accept referral fees, kickbacks, or "sponsored placement" in our directory. Our revenue model relies on anonymized aggregated data licensing to research institutions and a premium subscription for industry analysts, ensuring our patient-facing tools remain free and unbiased.